Pragmatic lifestyle interventions

What are the health benefits of pragmaticallyimplemented interventions (3-6 months) involving manageable amounts of supervised/home-based exercise and healthy eating advice in prostate and breast cancer patients?


Exercise and dietary intervention in men with locally advanced & metastatic prostate cancer receiving androgen deprivation therapy

Internal pilot: Bourke L, Doll H, Crank H, Daley A, Rosario DJ, Saxton JM (2011). *Cancer Epidemiol Biomarkers Prev. 20, 647-57.*

RCT: Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JW, Saxton JM, Rosario DJ (2014). *Eur Urol 65, 865-72.*



- Supervised and home-based aerobic and resistance exercise training 3-5 times per week for 12 weeks
- 3 month unsupported phase
- Nutrition advice pack encouraging reduction of saturated fat and refined carbohydrate and increase of dietary fibre intake with moderation of alcohol
- Fortnightly, small-group healthy eating seminars



Blood-borne biomarkers at baseline and after 3 months (internal pilot)

Baseline


End-point

	(n)	Usual care Mean (SD)	Intervention Mean (SD)	Usual care Mean (SD)	Intervention Mean (SD)	Group mean difference in Δ (95% CI)	Р
Insulin (mU.L ⁻¹)	42	10.8 (12.7)	10.4 (13.2)	11.7 (14.2)	8.91 (8.4)	-2.3 (-12.5, 7.8)	0.46
IGFBP3 (ng.ml ⁻¹)	42	3052.5 (750.7)	3098.1 (738.2)	2964.7 (796.2)	2875.7 (827.3)	-134.6 (-503.9, 234.6)	0.49
IGF-1 (ng.ml ⁻¹)	42	77.6 (25.8)	74.5 (21.5)	79.4 (27.2)	78.3 (22.6)	1.9 (-6.9, 10.8)	0.72
IGFBP-1 (ng.ml ⁻¹)	42	34.5 (24.4)	32.6 (25.9)	38.4 (26.2)	36.4 (26.4)	-0.18 (-12.1, 11.7)	0.91
PSA (ng.ml ⁻¹)	50	5.02 (10.2)	3.32 (6.83)	6.24 (13.6)	4.55 (8.74)	0.01 (-2.2, 2.2)	0.61
Serum Testosterone (nmol.L ⁻¹)	40	3.19 (6.97)	4.12 (8.69)	3.85 (8.67)	4.50 (8.01)	-0.28 (-1.8, 1.2)	0.68
Free Androgen Index	39	8.52 (19.4)	12.4 (24.3)	9.44 (21.5)	13.5 (22.8)	0.22 (-3.3, 3.8)	0.87
SHBG (nmol.L ⁻¹)	40	45.1 (13.6)	41.6 (13.2)	46.8 (14.0)	40.8 (11.8)	-2.5 (-6.4, 1.5)	0.13

Exercise and hypocaloric healthy-eating intervention in overweight women recovering from early-stage breast cancer treatment


Scott E, Daley AJ, Doll H, Woodroofe N, Coleman RE, Mutrie N, Crank H, Powers HJ, Saxton JM (2013). *Cancer Causes Control* 24, 181-191.

Saxton JM, Scott EJ, Daley AJ, Woodroofe M, Mutrie N, Crank H, Powers HJ, Coleman RE (2014). *Breast Cancer Res 16, R39.*




- 3 x weekly 30 min sessions of aerobic exercise using gym ergometers
- Resistance exercise (upper-body/trunk)
 - 3 sets of 12 reps with light handheld weights/resistance bands – arms, chest and back
 - Body weight resistance exercises, e.g. wall push-ups, etc.
- Encouragement to be more physically active/independent exercisers
- Personal nutrition advice based on achieving 600 kcal/day deficit and fortnightly group healthy eating sessions


Cardiopulmonary fitness



Beck Depression Inventory




FACT-B











Minimal effect on immune system





	Intervention group		Control group		P-	
	Baseline	Follow up	Baseline	Follow up	value	
Leukocyte counts						
Total leukocyte count (10 ³ cells/µl)	5.145 (1.417)	5.156 (1.337)	5.184 (1.237)	5.594 (1.370)	0.04	
Neutrophil count (10 ³ cells/µl)	3.014 (1.119)	2.958 (1.135)	3.131 (0.912)	3.377 (1.061)	0.05	
Monoctye count (10³ ce ll s/μ l)	0.400 (0.370, 0.430)	0.400 0.360, 0.440	0.400 (0.350, 0.450)	0.400 (0.350, 0.450)	0.63	
Lymphocyte count (10 ³ ce ll s/μ l)	1.507 (0.414)	1.523 (0.389)	1.446 (0.497)	1.612 (0.449)	0.04	
CD3 ⁺ CD4 ⁺ T cells (10 ³ cells/µl)	0.748 (0.596, 0.900)	0.682 (0.605, 0.759)	0.659 (0.532, 0.786)	0.763 (0.648, 0.878)	0.02	
CD3 ⁺ CD8 ⁺ T cells (10 ³ cells/µl)	0.474 (0.365, 0.583)	0.402 (0.334, 0.470)	0.360 (0.214, 0.506)	0.409 (0.322, 0.496)	0.05	
CD4 ⁺ :CD8 ⁺ ratio	1.62 (1.36, 1.88)	1.69 (1.40, 1.98)	1.93 (1.51, 2.35)	1.91 (1.49, 2.33)	0.87	
NK cells (10³ cells/µl)	0.200 (0.175, 0.225)	0.206 (0.177, 0.235)	0.176 (0.147, 0.205)	0.174 (0.144, 0.292)	0.46	
Inflammatory cytokines						
IL-6 (pg/mL)	1.599 (1.259, 1.906)	1.692 (1.377, 2.007)	1.755 (1.456, 2.054)	1.942 (1.602, 2.282)	0.93	
TNF-α(pg/mL)	0.889 (0.779, 0.999)	0.916 (0.767, 1.065)	1.058 (0.895, 1.221)	0.992 (0.870, 1.114)	0.61	

No effect of on sex steroid hormones, insulin sensitivity, insulin-like growth factors/ binding proteins or *hs*-CRP.

	4 D 1	A TTT
	Δ Body weight	Δ Waist circumference
Estradiol	-0.11	-0.14
Estrone	0.07	-0.13
Testosterone	0.09	0.06
SHBG	-0.29**	-0.31**
HOMA	0.21	0.12
IGF-1	-0.08	-0.39**
IGFBP-1	-0.06	-0.14
IGFBP-3	0.27*	0.14
Leptin	0.36**	0.35**
hs-CRP	0.33**	0.31**
Total cholesterol	0.23*	0.19
HDL cholesterol	0.06	-0.01

		,
Study details	Weight	Changes in cancer-
	loss	relevant biomarkers

Study details	Weight	Changes in cancer-
	loss	relevant biomarkers

Pakiz et al. (2011); Int J Behav Med 18, 333-341.

Rock et al. (2013); Clin Breast Cancer 13, 188-195. N=258 overweight or obese breast cancer survivors; 18

months (first 6 months more intensive) group-based D+E

N=42 overweight/obese breast cancer survivors: 12 weeks

Travier et al. (2018); Eur J Cancer Care, e12861.

of group-based D+E sessions; single group pre-post-

Imayama et al. (2012); Cancer Res 72, 2314-2326.

N=439 overweight/obese post-menopausal women; 12

months of dietician-led group based D, E or D+E sessions

van Gemert et al. (2015). Breast Cancer Res 17, 120.

N=243 overweight, inactive post-menopausal women; 16

(500 kcal/day deficit) or Mainly E (with 250 kcal/day deficit)

weeks of dietician and physiotherapist group-based D

of group-based D+E sessions versus control

sessions versus wait-list controls.

design.

versus control.

sessions versus controls.

N=68 overweight/obese breast cancer survivors; 16 weeks

Study details	Weight	Changes in cancer-	
	loss	relevant biomarkers	

6.8%

<5%

7.7%

>5% versus

D+E: 10.8%

Mainly E: 6.9%

D: 8.5%

E: 2.4%

D: 6.1%

Non-significant reductions in IL-6

(p=0.06) and TNF-a (p=0.05).

Reductions in insulin, leptin,

Reductions in glucose, insulin, C-

Reductions in hs-CRP, SAA and IL-6

in D & D+E groups with >5% weight

neutrophil counts in D+E with >5%

oestradiol and SHBG in D and D+E

groups; reduction in free testosterone

in mainly E group; intervention effects

were attenuated or disappeared after

adjustment for changes in body fat.

loss; reduced leucocyte and

Reductions in oestradiol, free

increased SHBG.


peptide, HOMA-IR.


weight loss.

More intensive combined exerc	ise and di	ietary interventions
Studv details	Weight	Changes in cancer-

McTiernan *et al.* 2011 – 2012

Multiple publications from the same study overweight/obese postmenopausal women: MVPA 45 min on 5 days per week and/or Hypocaloric diet













North of England Women's Diet and

ActivitY - After Breast Cancer Trial

(Acronym: NEW DAY-ABC)







Summary

- Structured exercise and/or physical activity brings health benefits to cancer survivors that go beyond weight loss.
- Studies show that exercise can enhance the effects of dietary interventions on body composition and cancer-relevant blood-borne biomarkers in cancer survivors.
- The provision of comprehensive dietary support is also needed for clinically-important body fat reduction in overweight/obese cancer survivors.

"Eating alone will not keep a man well; he must also take exercise... And it is necessary, as it appears, to discern the power of the various exercises, both natural exercises and artificial, to know which of them tends to increase flesh and which to lessen it..."

Hippocrates of Kos (c.460 – c.370 BC) Regimen I

